PDF(Pubmed)
Abstract：
Obesity is a chronic, multifactorial disease in which accumulated excess body fat has a negative impact on health. Obesity continues to rise among the general population, resulting in an epidemic that shows no significant signs of decline. It is directly involved in development of cardiometabolic diseases, ischemic coronary heart disease peripheral arterial disease, heart failure, and arterial hypertension, producing global morbidity and mortality. Mainly, abdominal obesity represents a crucial factor for cardiovascular illness and also the most frequent component of metabolic syndrome. Recent evidence showed that Tirzepatide (TZP), a new drug including both Glucagon Like Peptide 1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) receptor agonism, is effective in subjects with type 2 diabetes (T2D), lowering body weight, fat mass and glycated hemoglobin (HbA1c) also in obese or overweight adults without T2D. This review discusses the pathophysiological mechanisms and clinical aspects of TZP in treating obesity.
摘要：
肥胖是一种慢性,多因素疾病，其中积累过多的身体脂肪对健康有负面影响。肥胖在普通人群中持续上升，导致疫情没有明显下降的迹象。它直接参与心脏代谢疾病的发展，缺血性冠心病外周动脉疾病,心力衰竭,动脉高血压,造成全球发病率和死亡率。主要是,腹部肥胖是心血管疾病的一个重要因素，也是代谢综合征最常见的组成部分。最近的证据表明，TZP（TZP），一种包括胰高血糖素样肽1（GLP-1）和葡萄糖依赖性促胰岛素多肽（GIP）受体激动作用的新药，对2型糖尿病（T2D）患者有效，降低体重，没有T2D的肥胖或超重成年人的脂肪量和糖化血红蛋白（HbA1c）也是如此。本文综述了TZP治疗肥胖的病理生理机制和临床方面的研究进展。
